The first decade of MALDI protein profiling: A lesson in translational biomarker research

Journal of Proteomics

Volumn 74, Issue 6, 2011, Pages 765-773

  Albrethsen, Jakob ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Cancer; MALDI; Proteomics; SELDI; Translational research

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; CRYSTALLIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HUMAN; IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

BIOLOGICAL MARKERS; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEINS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79955462941     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.02.027     Document Type: Review

References (67)

1. Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006, 52(7):1223-1237.
2. McLerran D., et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 2008, 54(1):44-52.
3. McLerran D., et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008, 54(1):53-60.
4. Zhang Z., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64(16):5882-5890.
5. Taguchi F., et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007, 99(11):838-846.
6. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004, 3(4):367-378.
7. Lumbreras B., et al. Overinterpretation of clinical applicability in molecular diagnostic research. Clin Chem 2009, 55(4):786-794.
8. Check E. Proteomics and cancer: running before we can walk?. Nature 2004, 429(6991):496-497.
9. Ransohoff D.F. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005, 97(4):315-319.
10. Liotta L.A., et al. Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst 2005, 97(4):310-314.
11. Liotta L.A., Petricoin E.F. Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit. Clin Chem 2010, 56(10):1641-1642.
12. Petricoin E.F., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359(9306):572-577.
13. Huijbers A., et al. Proteomic serum biomarkers and their potential application in cancer screening programs. Int J Mol Sci 2010, 11(11):4175-4193.
14. Engwegen J.Y., et al. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest 2007, 87(2):161-172.
15. Rogers M.A., et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003, 63(20):6971-6983.
16. van Winden A.W., et al. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med Genomics 2009, 2:4.
17. Albrethsen J. Evaluation of type 1 diabetes serum cohort by SELDI protein profiling. Proteomics Clin Appl 2009.
18. Baggerly K.A., Morris J.S., Coombes K.R. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004, 20(5):777-785.
19. Giebel R., et al. Microbial fingerprinting using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) applications and challenges. Adv Appl Microbiol 2010, 71:149-184.
20. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 2007, 53(5):852-858.
21. Albrethsen J., et al. Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. Eur J Cancer 2006, 42(17):3057-3064.
22. Baggerly K.A., et al. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005, 97(4):307-309.
23. Szajli E., Feher T., Medzihradszky K.F. Investigating the quantitative nature of MALDI-TOF MS. Mol Cell Proteomics 2008, 7(12):2410-2418.
24. Wood W.G. "Matrix effects" in immunoassays. Scand J Clin Lab Invest 1991, (Suppl 205):105-112.
25. Duncan M.W., Roder H., Hunsucker S.W. Quantitative matrix-assisted laser desorption/ionization mass spectrometry. Brief Funct Genomic Proteomic 2008, 7(5):355-370.
26. Ekblad L., et al. In-source decay causes artifacts in SELDI-TOF MS spectra. J Proteome Res 2007, 6(4):1609-1614.
27. Albrethsen J., et al. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum. Clin Chem Lab Med 2006, 44(10):1243-1252.
28. NCCLS, Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. NCCLS Document EP6-A ((NCCLS. Wayne, PA), 2003.
29. Clark B.N., Gutstein H.B. The myth of automated, high-throughput two-dimensional gel analysis. Proteomics 2008, 8(6):1197-1203.
30. Valledor L., Jorrin J. Back to the basics: maximizing the information obtained by quantitative two dimensional gel electrophoresis analyses by an appropriate experimental design and statistical analyses. J Proteomics 2011, 74(1):1-18.
31. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24(8):971-983.
32. Fung E.T. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010, 56(2):327-329.
33. Karpova M.A., et al. Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives. J Proteomics 2010, 73(3):537-551.
34. Service R.F. Proteomics. Proteomics ponders prime time. Science 2008, 321(5897):1758-1761.
35. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1(11):845-867.
36. Roche S., et al. Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: the more the better?. J Proteomics 2009, 72(6):945-951.
37. Lopez M.F., et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem 2007, 53(6):1067-1074.
38. Petri A.L., et al. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand 2009, 88(1):18-26.
39. Karbassi I.D., et al. Proteomic expression profiling and identification of serum proteins using immobilized trypsin beads with MALDI-TOF/TOF. J Proteome Res 2009, 8(9):4182-4192.
40. Belluco C., et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol 2007, 14(9):2470-2476.
41. Banks R.E., et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005, 51(9):1637-1649.
42. Fung E.T., et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005, 115(5):783-789.
43. Timms J.F., et al. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin Chem 2007, 53(4):645-656.
44. Marshall J., et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003, 2(4):361-372.
45. Petricoin E.F., et al. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006, 6(12):961-967.
46. Villanueva J., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116(1):271-284.
47. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56(2):177-185.
48. Rodrigues C.A., et al. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 2010, 30(1):67-78.
49. Petrak J., et al. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008, 8(9):1744-1749.
50. Woo H.G., et al. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 2009, 69(9):4059-4066.
51. Chechlinska M., Kowalewska M., Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer. 2010, 10(1):2-3.
52. Khovidhunkit W., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45(7):1169-1196.
53. Brigden, M., The erythrocyte sedimentation rate. Still a helpful test when used judiciously. Postgrad Med, 1998. 103(5): p. 257=62, 272-4.
54. Peng J., et al. Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles - initial evaluation using low molecular weight serum peaks. Proteomics 2009, 9(2):492-498.
55. Albrethsen J., et al. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 2005, 5:8.
56. Villanueva J., et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 2006, 5(10):1840-1852.
57. Ward D.G., et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006, 94(12):1898-1905.
58. Vermeulen R., et al. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proc Natl Acad Sci USA 2005, 102(47):17041-17046.
59. Li J., et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005, 51(12):2229-2235.
60. Tolson J., et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004, 84(7):845-856.
61. Paradis V., et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005, 41(1):40-47.
62. Malik G., et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005, 11(3):1073-1085.
63. Sundsten T., et al. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci 2006, 4:22.
64. Moshkovskii S.A., et al. Ovarian cancer marker of 11.7kDa detected by proteomics is a serum amyloid A1. Proteomics 2005, 5(14):3790-3797.
65. Ye B., et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003, 9(8):2904-2911.
66. Hlavaty J.J., et al. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 2003, 61(6):1261-1265.
67. Koomen J.M., et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005, 11(3):1110-1118.